Fig. 1 | Bone Marrow Transplantation

Fig. 1

From: Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

Fig. 1

Survival rates according to the two additional cycles of VTD. a Progression-free survival (PFS): The 2-year PFS rate was 64.4 ± 5.0% and 68.9 ± 8.3% for the VTD4 and VTD6 groups, respectively (P = 0.189). b Overall survival (OS): The 2-year OS rate was 88.6 ± 3.2% and 95.4 ± 3.4 % for the VTD4 and VTD6 groups, respectively (P = 0.291)

Back to article page